Evommune Atopic Dermatitis Phase 2b Trial Misses Endpoints; Shares Down Pre-Bell

06:07 AM EDT, 09/09/2026 (MT Newswires) -- Evommune's (EVMN) phase 2b trial of EVO756 to treat adults with moderate-to-severe atopic dermatitis didn't meet its primary and secondary endpoints in any of the doses studied, the company said late Tuesday. The study enrolled 121 patients over a 12-week treatment period, with follow-up through week 14. Evommune said it doesn't intend to advance EVO756 in atopic dermatitis -- a chronic, itchy, and inflamed skin condition. The company's EVO301 fusion protein, which recently generated "positive" phase 2a proof-of-concept data, will enter a phase 2b trial planned for the middle of 2027, Chief Executive Luis Pena said. Evommune shares were down 17% in premarket activity Wednesday.